Encouraging Updates from Celcuity's Latest Clinical Trials
Celcuity Inc. (NASDAQ: CELC), a pioneering clinical-stage biotechnology company, has recently shared promising results from its Phase 1 clinical study evaluating the combination of gedatolisib and darolutamide for treating metastatic castration-resistant prostate cancer (mCRPC). These findings were delivered at a recent European medical conference, showcasing the potential of this novel approach in oncology.
Study Overview and Patient Demographics
The Phase 1 study included a total of 38 male patients diagnosed with mCRPC who had previously undergone treatment with next-generation androgen receptor inhibitors. Participants were divided into two groups, with one group receiving 120 mg gedatolisib and the other 180 mg, both to be taken alongside 600 mg of darolutamide. Each medication regimen was administered weekly for three weeks followed by a one-week break, while all patients received supportive treatment for stomatitis.
Key Findings: Progression-Free Survival Rates
Results from the study are particularly noteworthy. The median radiographic progression-free survival (rPFS) was reported to be 9.1 months, with an impressive six-month rPFS rate of 67%. The group receiving the 120 mg dose of gedatolisib revealed a six-month rPFS rate of 74% and a median rPFS of 9.5 months. Conversely, the 180 mg cohort had a six-month rPFS of 61% and a median of 7.4 months.
Safety and Tolerability of the Treatment Combination
Throughout the trial, this combination therapy was largely tolerated well by patients. Notably, there were no significant treatment-related adverse events that led to any participant discontinuing the study. Reported grade 3 adverse events included rash (5.3%), stomatitis (2.6%), and pruritus (2.6%), with no occurrences of grade 4 or 5 events being noted. In summary, the combination of gedatolisib and darolutamide generally proved safe and manageable for patients.
Future Directions and Clinical Trials
Dr. Igor Gorbatchevsky, Chief Medical Officer of Celcuity, expressed his optimism regarding the efficacy and safety data, comparing the results favorably to existing data on other androgen receptor inhibitors. Looking ahead, Celcuity plans to continue enrolling participants for the upcoming Phase 1/1b portion of the trial, during which they aim to identify the recommended Phase 2 dose for further clinical evaluation.
Amended Phase 1/1b Trial Details
The amended trial is set to recruit six patients per arm across three different dosage groups. Following the completion of the Phase 1 portion, an additional 40 patients will be integrated into multiple Phase 1b cohorts to assist in determining the recommended Phase 2 dosage. Further expansion into Phase 2 trials will include an estimated 30 subjects who will receive standard doses of darolutamide along with their specified protocols.
About Celcuity's Innovative Approach
Celcuity is committed to exploring targeted therapies for various types of solid tumors, with gedatolisib standing out as its lead candidate. This compound acts as a dual inhibitor on crucial cancer pathways, setting it apart from existing therapies that target only one of these pathways at a time. The company has already initiated a Phase 3 trial investigating gedatolisib in combination with fulvestrant for another breast cancer cohort, and they are actively recruiting for this promising study.
Frequently Asked Questions
What is the purpose of the Celcuity trial?
The trial evaluates the efficacy and safety of gedatolisib combined with darolutamide in men with metastatic castration-resistant prostate cancer.
How many patients participated in the study?
A total of 38 patients diagnosed with advanced prostate cancer participated in the Phase 1 study.
What were the key findings related to progression-free survival?
The median rPFS was 9.1 months, with a six-month rPFS rate of 67% across all treatment arms.
Was the treatment well tolerated by participants?
Yes, the combination was generally well tolerated, with no patients discontinuing due to treatment-related adverse events.
What are the next steps for Celcuity's research?
Celcuity plans to enroll more patients in the Phase 1/1b portion of the trial to determine the recommended Phase 2 dose.
